226 related articles for article (PubMed ID: 22464691)
1. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
2. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
3. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
4. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
Pawaskar M; Zagar A; Sugihara T; Shi L
J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
[TBL] [Abstract][Full Text] [Related]
6. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
8. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
9. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
Asche CV; Luo W; Aagren M
Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
11. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
12. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
Mittendorf T; Smith-Palmer J; Timlin L; Happich M; Goodall G
Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
[TBL] [Abstract][Full Text] [Related]
14. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
Buysman E; Conner C; Aagren M; Bouchard J; Liu F
Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
[TBL] [Abstract][Full Text] [Related]
16. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
[TBL] [Abstract][Full Text] [Related]
17. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
18. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
[TBL] [Abstract][Full Text] [Related]
20. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Reynolds MW
Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
